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PENILAIAN PENGURUSAN, HASIL RAWATAN DAN KUALITI KEHIDUPAN 
BERKAITAN KESIHATAN DALAM KALANGAN PESAKIT UBAT-UBATAN 
TUBERKULOSIS DI PESHAWAR, PAKISTAN 
 
ABSTRAK 
Secara global, Pakistan merupakan negara yang mempunyai multi-resistan 
terhadap pelbagai ubat-ubatan tuberkulosis (MDR-TB). Walaupun pengurusan 
pragmatik multi resistan drug terhadap TB (PMDT) di negara ini dimulakan dalam tahun 
2010, namun maklumat berkenaan pengurusan dan hasil rawatan pesakit dari Pakistan 
MDR-TB masih banyak yang belum diketahui.  Untuk tujuan ini, sejumlah 298 pesakit 
MDR-TB yang dirawat di unit PMDT di Hospital Lady Reading, Peshawar disertakan 
dalam tinjauan kajian kohort. Pesakit diberi rawatan susulan sehingga hasil rawatan 
direkodkan. Majoriti pesakit (55.8%) mempunyai tahap resistan terhadap ubat anti-TB 
pilihan kedua (SLD), dan kebanyakannya dari jenis fluoroquinolone (52.7%). Pesakit 
dengan rawatan TB terdahulu pada sektor campuran swasta dan awam lebih mudah 
mengalami ketahanan terhadap fluoroquinolone. Lebih separuh daripada mereka 
(53.6%) tiada kultur dalam masa beberapa bulan rawatan. Dalam analisis multivariat, 
ketahanan terhadap flouroquinolone dan penyakit kaviti paru-paru menjadi faktor risiko 
terjadinya kelewatan konversi kultur yang di lakukan.  Kesan buruk dihadapi seramai 
70.1% pesakit namun menjurus ke arah modifikasi rejimen rawatan TB sebanyak 18.9%.  
Pesakit dengan berat badan dasar > 40 kg  lebih mudah mendapat kesan buruk. Majoriti 
pesakit (75.1%) mencapai hasil rawatan yang berjaya. Dalam analisis multivariat, 
pesakit berusia >40 tahun, berat badan asas <40 kg, mempunyai ketahanan terhadap 
fluoroquinolone, penyakit  kaviti paru-paru dan modifikasi regimen akibat kesan buruk 
menjadi faktor risiko terhadap  hasil rawatan yang tidak berjaya.Tambahan pula di 
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sebalik kesan buruk MDR-TB ke atas Kualiti Kehidupan Berkaitan dengan Kesihatan 
pesakit serta terdapat banyak kekurangan maklumat  yang  berkaitan dengan kesan 
rawatan MDR-TB ke atas HRQoL pesakit. Bagi tujuan ini, seramai 81 pesakit MDR-TB 
yang layak (boleh membaca, umur > 18) telah di pilih menyertai kajian ini. Mereka 
diminta untuk melengkapkan sendiri soalselidik SF-36v2 pada lawatan permulaan, dan 
seterusnya, selepas melengkapkan rawatan selama 12 bulan dan pada akhir rawatan. 
Sejumlah 68 daripada 81 pesakit yang melengkapkan SF-36v2 pada tiga kali pertemuan. 
Keputusannya menunjukkan rawatan MDR-TB mendapat kesan positif ke atas HRQoL 
pesakit. Walaubagaimanapun, komponen fizikal pesakit (PCS) dan rumusan komponen 
tekanan mental (MCS) di dapati berada di bawah norma populasi normal. Jangkamasa 
keuzuran sebelum diagnosis MDR-TB di lakukan dapat memberi jangkaan perbezaan 
dalam kedua-dua skor PCS dan MCS, manakala jantina pesakit dapat memberi jangkaan 
perbezaan dalam MCS. Secara kesimpulannya, resistan yang tinggi terhadap 
flouoroquinolone amatlah membimbangkan sebagaimana yang diperolehi dari kajian ini. 
Kadar kejayaan rawatan agak menggalakkan namun masih boleh diperbaiki.  Walaupun 
kadar kesan advers terhadap ubat ubatan TB adalah tinggi, namun ianya tidak memberi 
kesan terhadap hasil rawatan secara negatif.  Walaupun pesakit-pesakit HRQoL beransur 
pulih sepanjang rawatan, namun ianya tidak begitu tinggi berbanding populasi secara 
umum sehingga ke akhir rawatan lengkap.  Faktor risiko penukaran kultur sputum yang 
tertangguh, kesan buruk, hasil rawatan yang tidak berjaya dan HRQoL yang rendah 
dapat dikesan sebelum atau pada awal rawatan.  Penumpuan yang lebih jitu dan amalan 
pengurusan rawatan secara klinikal yang lebih baik amatlah diperlukan bagi 
meningkatkan hasil rawatan dan HRQoL pesakit TB. 
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EVALUATION OF MANAGEMENT, TREATMENT OUTCOMES AND 
HEALTH RELATED QUALITY OF LIFE OF MULTIDRUG RESISTANT 
TUBERCULOSIS PATIENTS IN PESHAWAR, PAKISTAN 
 
ABSTRACT 
Globally, Pakistan is a multidrug resistant tuberculosis (MDR-TB) high burden 
country. Although, programmatic management of drug resistant TB (PMDT) in the 
country is initiated in 2010, but little is known about the management and treatment 
outcomes of MDR-TB patients from Pakistan. For this purpose, a total of 298 MDR-TB 
patients treated at the PMDT unit of Lady Reading Hospital Peshawar were included in 
an observational cohort study. Patients were followed until a treatment outcome was 
recorded. The majority of patients (55.8%) were resistant to second line anti-TB drugs 
(SLD), mainly a fluoroquinolone (52.7%). Patients with previous TB treatment at 
private and public private mix sectors were significantly more likely to be ofloxacin 
resistant. More than half of them (53.6%) achieved sputum culture conversion within 
first two months of treatment. In multivariate binary logistic regression analysis, 
resistance to fluoroquinolone and cavitary lung disease emerged as risk factors for 
delayed culture conversion. Adverse events were experienced by 70.1% patients, but led 
to TB treatment regimen modification for only 18.9%. Patients with baseline body 
weight >40 kg were significantly more likely to develop adverse events. The majority of 
patients (75.1%) achieved successful treatment outcome. In multivariate binary logistic 
regression analysis, patient’s age >40 years, baseline body weight <40 kg, resistance to 
fluoroquinolone, cavitary lung disease and regimen modification due to adverse events 
emerged as risk factors for unsuccessful treatment outcomes.  Moreover, despite 
potential detrimental effects of MDR-TB on patients Health Related Quality of Life 
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(HRQoL), there is lack of information regarding the effects of MDR-TB treatment on 
patients’ HRQoL. For this purpose a total of 81 eligible MDR-TB patients were enrolled 
at the study site. They were asked to self-complete SF-36v2 questionnaire at the baseline 
visit, and subsequently, after the completion of 12 months of treatment and at the end of 
treatment. A total of 68 out of 81 enrolled patients completed SF-36v2 at the three time 
points. The results revealed that MDR-TB treatment had a positive effect on patients’ 
HRQoL. However, even at the completion of treatment, patients’ physical component 
summary (PCS) and mental component summary (MCS) sores remained well below the 
general population norms. Length of sickness prior to the diagnosis of MDR-TB was 
predictive of differences in both PCS and MCS scores, whereas patient’s gender was 
predictive of difference in MCS score.  In conclusion, the high prevalence of 
fluoroquinolone resistance observed in the current study was alarming. The rate of 
successful treatment outcomes was encouraging but still has a room for further 
improvement. Despite high occurrence, adverse events did not impact treatment 
outcomes negatively. Patients’ HRQoL improved along the course of the treatment, but 
was inferior to that of general population norms even at the completion of the treatment. 
Risk factors for delayed sputum culture conversion, occurrence of adverse events, 
unsuccessful treatment outcomes and poor HRQoL are generally identifiable before or 
early in the course of treatment. Paying special attention and providing enhanced clinical 
management to the high risk patients may improve treatment outcomes and HRQoL. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background 
Tuberculosis (TB) is a highly infectious airborne disease caused by bacillus 
Mycobacterium tuberculosis (MTB). It has affected humanity throughout the known 
human history, and caused more human deaths than any other infectious disease (Daniel, 
2006). Even though, effective treatment strategies are available for TB, it still continues 
to be a critical health problem worldwide. Latest report of World Health Organization 
(WHO) estimated that, TB killed about 1.5 million people in 2014 __ equating to 4109 
deaths per day__ and ranked as the leading fatal infectious disease, surpassing human 
immunodeficiency virus (HIV).  In 2014, approximately 9.6 million TB cases occurred 
globally with an estimated incidence rate of 133 cases per 100,000 population (WHO, 
2015).   
Since 1990, the TB mortality rate has been declined by 47% (WHO, 2015). In 
the last 14 years, TB diagnostic and treatment interventions through efficient public 
health actions have saved an estimated 43.4 million lives globally (WHO, 2015), but 
unfortunately, the emergence and spread of drug resistant TB pose significant threats to 
these gains. Resistance to anti-TB drugs has been studied since 1940s (Wolinskye, et al., 
1948), but multidrug-resistant TB (MDR-TB) defined as “TB caused by the strain of 
MTB resistant to both isoniazid (Inh) and rifampicin (Rif)” came in the clinical literature 
and practice in early 1990s (Espinal, 2003; Frieden, et al., 1995; Kim, et al., 2003), and 
is now reported widely (WHO, 2015). Although, classical MDR-TB cases are curable, 
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but being resistant to isoniazid and rifampicin, the two most effective and well tolerated 
first-line anti-TB drugs, they are treated for prolonged periods with comparatively less 
potent, more toxic and expensive second-line anti-TB drugs (SLD) (Caminero, 2006; 
WHO, 2014a). The lack of evidence based recommendations from randomized control 
trials (Mitnick, et al., 2007), insufficient number of experts and diagnostic laboratories 
(Nathanson, et al., 2010), and prolonged therapy with comparatively less effective and 
potentially toxic regimen of multiple anti-TB drugs make it difficult to produce best 
possible treatment outcomes in MDR-TB patients (Bloss, et al., 2010; Caminero, 2006; 
Diel, et al., 2014; Sagwa, et al., 2014). Consequently, in 2014, the global treatment 
success rate of MDR-TB (50%) was significantly lower than that in drug susceptible TB 
patients (86%). Moreover, a large proportion of MDR-TB patients (25%) was lost to 
follow up or had no information about treatment outcomes (WHO, 2015). 
Besides poor treatment outcomes, the other major challenge faced during the 
treatment of MDR-TB is the high incidence and wide spectrum of adverse events 
(Avong, et al., 2015; Bloss, et al., 2010; Sagwa, et al., 2012; Sturdy, et al., 2011; Törün, 
et al., 2005; Wu, et al., 2016). These events range from life threatening reactions (renal 
failure and hypokalemia) and disabling effects (irreversible hearing and vision loss) to 
non-life-threatening reactions (gastrointestinal disturbances) of negative impact on 
patients’ quality of life (Avong, et al., 2015), and may need a temporary or permanent 
discontiuation of the culprit drug(s) (Bloss, et al., 2010; Furin, et al., 2001; Hoa, et al., 
2015; Törün, et al., 2005). Adverse events may negatively affect patients’ compliance, 
require hospitalization, and result in increased health care costs, morbidity and mortality 
(Leimane, et al., 2005; Nathanson, et al., 2004; Törün, et al., 2005). 
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Health Related Quality of Life (HRQoL) defined as “the extent to which 
patient’s subjective perception of physical, mental and social wellbeing is affected on a 
day to day basis by a disease and its treatment(s)” (Leidy, et al., 1999) is an important 
patient reported outcome. It quantifies that how the disease and its treatment affect the 
lives of the patients, and aims to measure the quality rather than only the quantity of 
health (Guo, 2010). Multidrug-resistant tuberculosis being a contagious, chronic and 
debilitating disease of prolonged chemotherapy with potentially toxic drugs, results in 
high incidence of adverse events and long term physiological, socio-economic and 
psychological effects (Booker, 1996; Furin, et al., 2014; Isaakidis, et al., 2013). All 
these factors can adversely affect the HRQoL of MDR-TB patients (Al-Qahtani, et al., 
2014; Kittikraisak, et al., 2012; Morris, et al., 2013; Sharma, et al., 2014). 
Pakistan is an MDR-TB 5th high burden country (WHO, 2015). Programmatic 
management of drug resistant TB (PMDT) in the country is initiated in 2010, and in 
2013, there were 18 functional PMDT units throughout the country (NTP, 2013a), but 
little is known about the management and treatment outcomes of MDR-TB patients from 
Pakistan, particularly after the implementation of PMDT in the country. Moreover, 
despite a chronic contagious disease of prolonged chemotherapy with potentially toxic 
SLD, and negative impact on patients physical, mental, social and economic wellbeing, 
evaluating the effects of MDR-TB treatment on patients HRQoL has remained a 
neglected area. Therefore, the current study focused on evaluating the management, 
treatment outcomes and effects of MDR-TB treatment on patients HRQoL at a PMDT 
unit in Pakistan.  
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1.2 Origin of drug-resistant tuberculosis 
Resistance to anti-TB drug is not a new phenomenon. It appeared soon after the 
discovery of anti-TB drugs (Crofton & Mitchison, 1948). All chemotherapeutic agents 
used to treat bacterial infections tend to produce resistant strains. The resistance may be 
primary or secondary. Primary drug resistance refers to the “drug resistance in a patient 
who has not received the drug before” (Telenti & Iseman, 2000). During rapid 
multiplication of bacilli, resistant mutants emerge irrespective of the administration of 
any particular agent (Zhang & Yew, 2009). It is believed that primary drug resistance is 
induced by the transference of non-chromosomal heritable genes called “episomes”. If 
an episome containing resistant cell comes in direct contact with a susceptible cell, 
episome leaves the resistant cell and invade the susceptible one (Cohen, et al., 1972). 
Secondary drug resistance also known as acquired drug resistance refers to the 
“resistance developed during the course of antimicrobial therapy” (Telenti & Iseman, 
2000). In acquired drug resistance, bacteria develop resistance to particular drugs to 
which they were sensitive at the start of the treatment (Telenti & Iseman, 2000). 
1.3 Mechanism of development of drug resistance in Mycobacterium tuberculosis   
Antimicrobials agents used to treat infections have the ability to actively inhibit 
or kill microorganisms. The interruption or disturbance of one or more steps necessary 
for antimicrobial action results in the emergence of antimicrobial resistance. Because of 
base changes caused by exogenous agents, deoxyribonucleic acid (DNA) polymerase 
errors; deletion, insertion and duplication, random spontaneous mutations continuously 
occur at a low frequency in all bacterial population (Drake, 1999). Some of these 
mutations may confer resistance to a particular antimicrobial agent by several 
mechanisms. These mechanisms include the production of proteins that modify the 
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binding site for antimicrobial, enzymes that destroy it, and proteins that reduce its 
permeability and change of the metabolic pathway of antimicrobial within the bacteria 
so, that its efficacy is reduced (Dever & Dermody, 1991; Hawkey, 2000). The biological 
consequence of mutation determines the degree of resistance conferred by chromosomal 
mutation. With less common single large step mutations, the drug target is altered such 
that it becomes completely unable to bind the drug. In such case, the resistant mutant is 
capable to survive and grow, and eventually becomes the predominant or only strain of 
the population (Drlica, 2003). In the more common multiple step pattern of resistance, 
the drug target is altered in such a way that despite having some residual affinity, it is 
unable to bind the drug that efficiently. In such cases, higher concentrations of drug 
would be required for producing antimicrobial effect (Drlica, 2003). Once a slightly 
resistant strain has been produced, consequent mutational events confer additional 
degree of resistance to the strain and make it highly resistant (Long, 2000; Telenti & 
Iseman, 2000; Zhang & Yew, 2009).  
Unlike other bacteria, where drug resistance is caused by horizontal transfer of 
mobile genetic elements such as plasmids, integrons or transposons; drug resistance in 
MTB is mediated mainly through spontaneous chromosomal mutations at a frequency 
ranging from10-6-10-8 mycobacterial replications (David, 1970; Kochi, et al., 1993; 
Telenti & Iseman, 2000). As chromosomal mutations are unlinked and spontaneous, 
shift from an isoniazid susceptible MTB to a population with 1% resistance would take 
5,000 to 10,000 years (David & Newman, 1971), suggesting that mycobacterial 
resistance in the presence of three effective anti-TB drugs is high unlikely. However, the 
suboptimal treatment regimen, mono-therapy, irregular intake of drugs, low drug 
penetration due to empyema, solid caseous material and extensive cavitation impose 
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artificial selection power in bacteria (Zhang and Yew, 2009). Under such selective 
pressure, the drug susceptible strains are killed and the genetic mutants being naturally 
resistant to the given antibiotic flourish, resulting in the conversion of drug susceptible 
TB to a mono-resistant one (Mitchison, 1954). Upon exposure to a second course of 
therapy with yet another anti-TB drug, genetic mutants being naturally resistant to the 
given drug emerge as dominant strains, generating poly-resistant strains including MDR-
TB strains (Rattan, et al., 1998; Zhang & Yew, 2009). Concepts of development of drug 
resistant TB are given in Fig 1.1 (Zhang & Yew, 2009). 
 
  
                                                                          
 
 
 
                                                                                 
            
  
 
  
  
   
          
 
 
 
 
Fig. 1.1 Concepts of development of drug resistant tuberculosis 
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Acquired drug resistance 
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The emergence and prevalence of drug resistant TB has a strong correlation with 
the past and present management of TB (Caminero, 2010). It can be avoided by 
successfully treating the drug susceptible TB. Countries with a high incidence and 
prevalence of drug resistant TB have a history of poor TB control programs (WHO, 
2009). Multiple, and often the combination of various risk factors are responsible for the 
emergence of drug resistant TB. These factors include i) healthcare related factors like 
previous faulty TB treatment (Caminero, 2010; Chen, et al., 2013; Espinal, et al., 2001; 
Liang, et al., 2012), no or poor implementation of DOTS (Aguilar, et al., 2005; Chacón, 
et al., 2009), substandard anti-TB preparations (Lambregts-van Weezenbeek & Veen, 
1995; Wells, et al., 2011), erratic or interrupted supply of drugs (Chen, et al., 2013; 
Lambregts-van Weezenbeek & Veen, 1995), guidelines divergent practices by 
practitioners (Achanta, et al., 2013; He, et al., 2011; Shah, et al., 2003), patients’ non-
adherence with anti-TB treatment (Ejaz, et al., 2010; Sharma, et al., 2003; Volmink & 
Garner, 2007), and ii) patients related factors like co-infection with HIV (Faustini, et al., 
2006; Joseph, et al., 2006; Pereira, et al., 2005), diabetes mellitus (Gomes, et al., 2014; 
Rifat, et al., 2014), patients age (Atre, et al., 2011; Rifat, et al., 2014), gender (Ejaz, et 
al., 2010; Faustini, et al., 2006), close contacts with MDR-TB (Martínez, et al., 2010; 
Vella, et al., 2011) and residence in overcrowded or congregate settings like refugee 
camps, prisons (Andrews, et al., 2007; Habeenzu, et al., 2007) etc.  
1.4 Epidemiology of MDR-TB 
1.4.1 Global epidemiology of MDR-TB 
According to Global Tuberculosis Report 2015, MDR-TB accounts for 5% of all 
TB cases. It is estimated that in 2014, a total of 480,000 (95% confidence interval [CI]: 
360,000-600,000) new MDR-TB cases emerged globally with an estimated proportion 
  
8 
 
of 3.5% of new cases and 20% of previously treated cases (WHO, 2015). Twenty seven 
MDR-TB high burden countries accounted for more than half of the estimated MDR-TB 
cases in 2014. Three countries; India, China and Russian Federation make more than 
half of the global MDR-TB burden. Among notified pulmonary TB cases, India has the 
highest estimated MDR-TB cases (71,000) followed by China (52,000) and Russian 
Federation (39,000). Among new cases, the percentages with MDR-TB were highest in 
Belarus (34%) followed by Kyrgyzstan (26%) and Kazakhstan (26%). Among 
retreatment TB cases, the percentages with MDR-TB were highest in the Belarus (69%) 
followed by Estonia (62%) and Republic of Moldova (62%) (WHO, 2015).   
1.4.2 Epidemiology of MDR-TB in Pakistan 
Tuberculosis is an endemic and major public health problem in Pakistan (Javaid, 
2011; Khan, et al., 2000; NTP, 2013b; Vermund, et al., 2009). Sadly, despite the critical 
nature of the problem and high prevalence of TB in the country, it remained a forgotten 
area in the past. TB control was almost nonexistent in the country until the revival of 
National TB Control Program (NTP) in 2001 (Vermund  et al., 2009; Javaid, 2011). 
First TB survey in Pakistan took place in 1962, the results of which led to the 
establishment of collaborative efforts for TB control between Ministry of Health 
Pakistan, WHO and United Nations International Children Emergency Fund (UNICEF) 
(De Muynck, et al., 2001; Javaid, 2011). The said collaboration mainly focused on 
establishing the specialized TB treatment centers and wards at the district headquarter 
hospitals (De Muynck  et al., 2001; Javaid, 2011). Unfortunately, in 1985 UNICEF 
withdrew its financial support. In order to achieve effective TB control after WHO 
declaration of TB as a global emergency, Government of Pakistan piloted Directly 
Observed Treatment- Short course (DOTS) strategy at five sites in 1995, but only one 
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remained operational. Despite revised TB control policy in 1994 and the drafted national 
policy and technical guidelines for TB control, in 1998 Pakistan was declared as a 
country without a proper functional NTP (De Muynck, et al., 2001). In 2000, the 
estimated percentage of case detection rate for new and relapse smear-positive cases–a 
key indicator of a successful TB control program–was 2.8%, far below the WHO target 
of > 70% (WHO, 2009).  
Since the revival of NTP and nationally adopting DOTS in 2001 (NTP, 2013a; 
Vermund, et al., 2009), Pakistan has made enormous progress regarding DOTS 
coverage, TB case notification and treatment success rates. It took four years to bring 
DOTS coverage to all public health facilities in the country (Javaid, 2011; NTP, 2013a; 
Vermund, et al., 2009). In Pakistan, 100% population had DOTS coverage in 2005 as 
compared to only 8% in 1998 (WHO, 2009). Estimate of the case detection rate for new 
and relapse cases has been increased from 3.9% in 1995 to 62% in 2014 (WHO, 2015). 
Moreover, TB treatment success rate has been increased from 70% in 800 treated 
patients in 1995 to 93% in 289,376 treated cases in 2013 in the country (WHO, 2015). 
Despite remarkable progress regarding DOTS coverage, TB case notification and 
treatment success rate in the last decade, Pakistan still ranks 6th among the 22 TB high 
burden countries. According to WHO latest report, Pakistan accounts for 68% of TB 
burden in Eastern Mediterranean Region of WHO (EMRO) with estimated incidence of 
500,000 (95% CI: 370,000-650,000) and prevalence of 630,000 (95% CI: 530,000-
740,000) (WHO, 2015). Similar to other developing countries, people aged > 15 years 
were the most affected group in Pakistan. In 2014, the estimated deaths attributed to TB 
in the country were 48,000 with a mortality rate of 26 per 100,000 population (WHO, 
2015). 
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Unfortunately, in the last 25 years, consistent increase in the incidence of drug 
resistant TB including MDR-TB has been observed in the country (WHO, 2014b; 
Hasan, et al., 2009). As in the early 2000, the management of drug resistant TB was not 
included in NTP; there was a scarcity of data regarding the prevalence of drug resistant 
TB in the country. Previously conducted studies which evaluated drug resistance trends 
in MTB isolates from all over the country have reported a significant increase in 
prevalence of MDR-TB in the country (5.5% in 1990, 33.1% in 2007 and 34.1% in 
2009) (Hasan, et al., 2009; Jabeen, et al., 2011). However, the results of these studies 
should be interpreted with the notable limitation of passive case finding designs, where 
majority of the cases referred from all over the country were either treatment failures or 
complicated cases. 
With the adoption PMDT in 2010 and improved efficiency of NTP, the 
notification of MDR-TB cases in Pakistan has been increased. In comparison to the 40 
notified cases among the estimated 8290 cases in 2008, a total of 3243 MDR-
TB/rifampicin resistant TB cases of the estimated 12000 cases have been notified in 
2014 (WHO, 2015; WHO, 2008a).  Due to the lack of surveillance system to monitor 
drug resistance in the country, the most recent data available on drug resistant TB from 
Pakistan is the trend data generated through special survey conducted from 2010-2013. 
In 2014, a total of 316,577 TB cases were notified in the country including 3,243 cases 
of MDR-TB (WHO, 2015). In terms of MDR-TB burden, Pakistan ranks MDR-TB 5th 
high burden country globally and harbors the largest population of MDR-TB patients in 
EMRO. According to WHO latest report, it is estimated that in 2014, a total of 12,000 
(95%CI: 8,800-15,000) MDR-TB cases emerged in Pakistan with an estimated 
proportion of 3.7% of new cases and 18% of previously treated cases (WHO, 2015). 
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Despite reported TB treatment success rate of 91% with 72% cure rate in the country 
(NTP, 2013a), such a high prevalence of MDR-TB with relatively low primary drug 
resistance, raises the possibility that a significant proportion of TB patients receiving 
treatment in private sector are not included within the DOTS program (Hasan, et al., 
2009). Notified TB cases in Pakistan from 2008-2014 have been given in Table 1.1. 
Table 1.1 Notified tuberculosis cases in Pakistan (2008-2014) 
 2008 2009 2010 2011 2012 2013 2014 
All TB cases 
(notified) 
245635 316864 269290 270394 273097 298446 316577 
New Cases 240695 301867 255329 255094 261380 282607 300350 
Relapse + 
Retreatment cases 
4940 14997 13691 15300 11717 15839 16227 
Estimated MDR- 
TB among notified 
pulmonary TB 
8290 9800 9700 - 11000 13000 12000 
Notified MDR-TB 
Cases 
40 49 444 344 1602 2596 3243 
TB, tuberculosis; MDR, multidrug resistant; (WHO reports 2009- 2015) 
 
1.5 Management of MDR-TB in Pakistan 
After implementation of PMDT strategy in June 2010, MDR-TB in Pakistan is 
treated under a uniform protocol guided by national guidelines for PMDT (NTP, 2012). 
These guidelines were drafted in 2008 and updated in 2012. Table 1.2 provides details 
about anti-TB drugs used for the treatment of drug resistant TB in Pakistan.  
   
 
 
12 
Table 1.2 Details of most commonly anti-TB drugs used for the management of MDR-TB in Pakistan 
Group Drug name 
(abbreviation) 
Recommended dose Common adverse effects 
Daily dose 
(mg/kg body 
weight) 
Maximum dose 
(mg) 
Group 1. First-line oral 
agents 
Ethambutol (Emb) 25 1600-2000 Visual impairment 
Pyrazinamide (Pza) 30-40 2000-2500 GI disturbance, photo-sensitization,  
jaundice, hepatitis,  arthralgia 
Group 2. Injectable anti-
TB drugs 
Kanamycin (Km) 15-20 1000 Ototoxicity, nephrotoxicity 
Amikacin (Amk) 15-20 1000 
Capreomycin (Cm) 15-20 1000 
Group 3. 
Fluoroquinolones 
Levofloxacin (Lfx) 7.5-10 750-1000 GI disturbances, insomnia, headache, 
 thrush, anxiety, allergic reactions, tremors Moxifloxacin (Mfx) 7.5-10 400 
Group 4. Oral 
bacteriostatic SLD 
Ethionamide (Eto) 15-20 750-1000 GI disturbances, metallic taste,  
Salivation. hepatitis, peripheral neuropathy Prothionamide (Pto) 15-20 750-1000 
Cycloserine (Cs) 15-20 750-1000 Dizziness, headache, depression, memory 
 loss, psychosis 
Para-aminosalicylic acid 
(PAS) 
150 8-12 gm GI disturbances, drug fever, cutaneous 
reactions 
Group 5. Anti-TB drugs 
with limited data on 
efficacy 
Amoxicillin/Clavulanate 
(Amx/Clv) 
Dosages for drug resistant TB not 
well defined. Normal adult dose is 
875/125 mg twice daily or 500/125 
mg three times a day 
GI disturbances, cutaneous reactions,  
headache 
Clarithromycin (Clr) Usual adult dose is 50 mg twice daily  
GI, gastro-intestinal; SLD, second-line anti-TB drugs 
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According to national guidelines, presumed MDR-TB patients referred to a 
PMDT unit should be initially evaluated for the presence of AFB and rifampicin 
resistance by using smear microscopy and rapid drug susceptibility testing (DST). For 
rapid DST, GeneXpert MTB/RIF (Mycobacterium tuberculosis/rifampicin) assay which 
is a nucleic acid amplification assay should be used. This test concurrently detects MTB 
and resistance to rifampicin in less than 2 hours.  
Upon positive sputum smear microscopy and rifampicin resistance, patient 
should be enrolled for MDR-TB treatment with empirical treatment regimen, and the 
specimen sample should be sent to a reference laboratory for culture and DST against 
both first and SLD. Upon reception of DST results, patients should be switched from 
empirical regimen to DST based individualized regimen. 
National guidelines have outlined the following general principles for MDR-TB 
treatment: i) treat the patients with at-least four likely effective SLD plus pyrazinamide 
ii) avoid drugs for which resistance crosses over iii) eliminate the drug not safe for the 
patient  iv) remain ready to prevent, observe and manage adverse effects for each 
selected drug. 
According to national guidelines, following drugs should be included for 
devising a DST based individualized treatment regimen:  
a) any available first line oral anti-TB drug 
b) an injectable SLD 
c) a fluoroquinolone  
d) two or more second line oral bacteriostatic SLD until the goal of four likely 
effective SLD is achieved 
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e) if four likely effective anti-TB drugs from Group 2-4 are not possible, 
consider the addition of Group 5 drugs.  
Because of higher incidence of ototoxicity and resistance against streptomycin in 
patients with drug resistant TB, streptomycin should not be the part of MDR-TB 
treatment regimen even if DST suggests susceptibility. National TB control program 
supports individualized treatment regimen if DST to first-line and SLD is available. 
Otherwise, treatment in a presumed MDR-TB patient should be initiated with an 
empirical regimen based on patient’s history of TB treatment.  
National guidelines have outlined the following general principles for initiating 
treatment in a presumed MDR-TB patient: 
i) Treatment in patients with no history of previous use of SLD should be initiated with:  
Amikacin/kanamycin/capreomycin + levofloxacin + ethionamide + cycloserine + 
pyrazinamide 
ii) Treatment in patients with a documented history of previous use of fluoroquinolones 
should be initiated with: 
Amikacin/kanamycin/capreomycin + levofloxacin + ethionamide + cycloserine + para-
amino salicylic acid + pyrazinamide 
iii) Treatment in patients with documented history of previous use of injectable SLD 
should be initiated with: 
Capreomycin + levofloxacin + ethionamide + cycloserine + para-amino salicylic acid+ 
pyrazinamide 
MDR-TB treatment is divided into two phases; the intensive phase and the 
continuation phase. The time the patient is on injectable SLD is referred to as the 
intensive phase. The duration of intensive phase is guided mainly by sputum culture 
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conversion defined as “two consecutive negative sputum cultures taken at least 30 days 
apart following an initial positive culture” (Holtz, et al., 2006) and should be continued 
for at least eight months with a minimum of six months after sputum culture conversion. 
However, other clinical indicators like weight gain, resolution or improvement of 
respiratory symptoms and/or pulmonary lesions can also be taken in consideration while 
deciding about the duration intensive phase. During continuation phase, only the 
injectable SLD is discontinued and the patient continues to take the same oral drugs 
which he/she was using at the end of intensive phase. A new MDR-TB patient should be 
treated for a minimum of 20 months, at-least 18 months past culture conversion (NTP, 
2012). 
1.6 Treatment outcomes of MDR-TB patients 
In 2014, among 1.5 million TB related deaths worldwide, 0.19 million were 
attributed to MDR-TB (WHO, 2015). As MDR-TB patients are resistant to isoniazid and 
rifampicin, they are treated with SLD for a prolonged period of >20 months. The 
comparatively less effective and potentially more toxic nature of SLD make it difficult 
to achieve the desired treatment success rate in MDR-TB treatment (Caminero, 2006; 
Sharma & Mohan, 2004). This is very obvious from the recently reported significantly 
lower global treatment success rate in MDR-TB (50%) as compared to treatment success 
rate in drug susceptible TB (86%). In 2014, only 43 out 127 countries and territories that 
reported treatment outcomes for 2012 cohort of MDR-TB patients achieved the WHO 
target treatment success rate (>75%) (WHO, 2015). In a recently published study, 
Falzon et al., (2015) reported that the median treatment success rate among 30,021 
MDR-TB patients from 25 countries was 53% (IQR 40-70%), and in comparison to 87% 
of drug susceptible TB patients only half of MDR-TB patients completed treatment. 
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The lower treatment success rate among MDR-TB patients is corroborated by the 
findings of the published systematic reviews. In a systematic review of 64 cohorts of 
MDR-TB patients, Akcakir (2011) reported a pooled treatment success rate of 50% 
(95% CI 46-59%). Treatment for > 20 months, individualized treatment regimen, use of 
> 3 likely effective drugs and use of fluoroquinolones or use of SLD in general were 
predictors of successful treatment outcomes. The study reported that, mortality rate was 
significantly high in patients co-infected with HIV and those who were on < 3 likely 
effective drugs, whereas the use of SLD was significantly associated with high default 
rate.  
In a systematic review which included MDR-TB patients of 31 programs from 
21 countries, Johnston et al., (2009) have reported a pooled treatment success rate of 
62% [95% CI: 57-67]. The authors reported that male gender, low body mass index 
(BMI), alcohol abuse, resistance to fluoroquinolones, smear positive status at the 
diagnostic visit and presence of and extensive drug resistance (XDR) pattern were the 
risk factors for unsuccessful treatment outcomes. Patients with no history of previous TB 
treatment, and those who received fluoroquinolones and surgical intervention were more 
likely to develop successful treatment outcomes.  
Orenstein and colleagues (2009) in a systematic review of 33 studies from 20 
countries, reported a similar percentage (62%, 95%CI: 58-67%) of favorable treatment 
outcomes in MDR-TB patients. However, they observed an improved pooled treatment 
success rate (69%) for those studies in which the patients received the combination of 
treatment for more than 18 months and DOT throughout the treatment duration.  
Ahuja et al., (2012) conducted a meta-analysis of an individual patient data of 
9,153 pulmonary MDR-TB patients. Among the studied patients, only 54% achieved 
  
17 
 
successful treatment outcomes. The multivariate analysis revealed the use of later 
generation fluoroquinolones, ofloxacin and thioamides, and receiving 4> likely effective 
drugs in the intensive phase of treatment as predictors of successful treatment outcomes. 
In order to effectively manage and achieve best possible treatment outcomes in 
drug resistant TB, the WHO and its partner agencies devised and launched DOTS-Plus 
strategy in 1998 (Bastian, et al., 2000; Farmer & Kim, 1998). Basic principles of this 
strategy are: i) sustained political commitment ii) precise and timely diagnosis of drug 
resistant TB through quality assured culture and DST iii) uninterrupted supply and 
appropriate use of quality assured first-line and SLD iv) DOT and v) standardized 
recording and reporting system.  
Later on, to ensure the effective implementation of DOTS-Plus strategy and 
devise “Models of Good Practice” for MDR-TB treatment, the WHO along with its 
international partners established a committee known as the “Green Light Committee” 
(GLC) (Cobelens, et al., 2008; Gupta, et al., 2002). This committee provides technical 
support for implementing the DOTS-Plus protocol and makes it sure that standards are 
met before initiating DOTS-Plus program at any site. Furthermore, GLC by linking up 
with drug manufacturers also facilitates the continuous supply of quality assured SLD at 
concessional prices (Cobelens  et al., 2008). On the basis of experience from successful 
implementation of DOTS-Plus projects at five resource poor settings and achieving 
promising results of MDR-TB treatment success rate of 59-83% (Nathanson, et al., 
2006), WHO devised and issued guidelines for what is now called PMDT (WHO, 
2008b). Updated guidelines and a companion handbook to the WHO guidelines for 
PMDT have been issued in 2011 and 2014 respectively (WHO, 2011b; WHO, 2014).  
DOTS-Plus strategy (Bastian, et al., 2000; Farmer & Kim, 1998) has been proven 
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feasible, cost effective and having a greater impact on reducing mortality in MDR-TB 
patients particularly in high burden areas and resource poor settings (Sterling et al., 
2003; Tupasi, et al., 2006). Table 1.3 presents the treatment success rates of MDR-TB 
patients treated under DOTS-plus or PMDT strategy. 
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Table 1.3 Treatment outcomes of MDR-TB patients treated under DOTS-Plus strategy 
Study Country Data  
Collection 
Sample 
size (n) 
Patients 
enrollment 
Period 
Type of  
regimen  
HIV 
Positive 
(%) 
Treatment 
Success (%) 
van der Walt, et al.,2016 South Africa Retrospective 671 2000-2008 STR 59% 65 
Akshata & Chakrabarthy, 
2016 
India Retrospective 69 2011-2012 STR 4.4 47.8 
Kapadia & Tripathi, 2016 India Retrospective 102 2007-2014 STR 2.9 45.1 
Patel, et al., 2015 India Retrospective 145 Feb-Dec 2010 STR 1.3 38.6 
Gadallah, et al., 2015 Egypt Prospective 228 2006-2010 ITR - 69.3 
Bastard, et al., 2014 Armenia &  Georgia Retrospective 393 2002-2010 ITR - 56.5 
Jain, et al., 2014 India Prospective 130 Jan-Dec 2009 STR -- 45 
Rodriguez, et al., 2013 Dominican Republic Retrospective 150 2006-2010 STRµ-ITR£ -- 72 
Chan, et al., 2013 Taiwan Retrospective 651 2000-2008 ITR 0.9 69.3 
Kurbatova, et al., 2012 Russia, Peru, Estonia 
Latvia, Philippines  
Retrospective 
 
1768 2000-2004 ITR 
 
1.6 65.4 
Farley, et al., 2011 South Africa Retrospective 757  STR 5 46 
Joseph, et al., 2011 India Prospective 37 2006-2007 STR -- 66 
Leimane, et al., 2010 Latvia Retrospective 979 2000-2004 ITR 23 69.3 
Singla, et al., 2009 India Retrospective 126 2002-2006 STR -- 61 
Malla, et al., 2009 Nepal Prospective 175 2005-2006 STR -- 70 
Keshavjee, et al., 2008 Russia Retrospective 579 2000-2004 ITR 0.8 66.7 
Cox, et al., 2007 Uzbekistan Prospective 87 2003-2005 ITR -- 62 
Shin, et al., 2006 Russia Retrospective 244 2000-2002 ITR -- 77 
Tupasi, et al., 2006 Philippines Prospective 117 1999-2002 ITR - 61 
Holtz, et al., 2006 Latvia Retrospective 178 Jan-Dec 2001 ITR -- 65 
Nathanson, et al., 2006 Estonia, Latvia, Russia 
Peru, Philippines & 
Retrospective 1047 1999-2001 ITR 
 
1.7* 69.6 
Leimane, et al., 2005 Latvia Retrospective 204 2000-2004 ITR 1.5 66 
Leimane, et al., 2005  Latvia Retrospective 204 Jan-Dec 2001 ITR 0.5 66 
Van Deun, et al., 2004 Bangladesh Prospective 58 21 months STR -- 69 
DOTS, Directly Observed Treatment Strategy; Feb, February; Dec, December; Jan, January; ITR, individualized treatment regimen; STR, standardized 
treatment regimen;  *HIV testing was not performed in Manila; µn=105; £n=45 
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1.7 Risk factors for unsuccessful treatment outcomes among MDR-TB patients 
1.7.1 Previous TB treatment 
Previous TB treatment with and without exposure to SLD is not only a risk factor 
for the emergence of drug resistant TB (Caminero, 2010; Chen, et al., 2013; Liang, et 
al., 2012) but is also widely reported as a risk factor for unsuccessful treatment 
outcomes in MDR-TB patients. Kliiman and Altraja (2009) have reported three times 
greater risk of unsuccessful treatment outcomes in MDR-TB patients who had a history 
of previous TB treatment. A study conducted in Turkey has also reported previous 
exposure to SLD as a predictor of unfavorable outcomes in MDR-TB patients 
(Tahaoğlu, et al., 2001). Similarly, Kurbatova and colleagues (2012) have reported a 
significantly greater risk of death and treatment failure among MDR-TB patients who 
had a history of previous use of SLD. On the other hand, absence of previous TB 
treatment among MDR-TB patients has been reported as a predictor of successful 
treatment outcome (Johnston, et al., 2009; Milanov, et al., 2015). Amplification of drug 
resistance due to faulty TB treatment in the past and patients’ poor adherence with 
therapy could be the possible reason of poor outcomes in MDR-TB patients with a 
history of previous TB treatment (Kliiman & Altraja, 2009; Kurbatova, et al., 2012). 
1.7.2 Co-infection with Human Immunodeficiency Virus 
HIV reduces immunity, predisposes patients to infections and activates latent 
one. In 2014, there were an estimated 1.2 million new HIV positive TB cases (12% of all 
TB cases). Out of 1.5 million deaths from TB, 390,000 deaths were among HIV positive 
TB patients (WHO, 2015). HIV co-infection in MDR-TB patients significantly increases 
the risk of unsuccessful outcomes (Burgos, et al., 2005; Farley, et al., 2011; Flament-
Saillour, et al., 1999; Kliiman & Altraja, 2009; Kurbatova, et al., 2012; Mannheimer, et 
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al., 1997; Uffredi, et al., 2007). Concurrent presence of MDR-TB and HIV infection 
puts the clinicians in multiple challenges. HIV positive patients are more likely to have 
sputum negative and extra-pulmonary TB (WHO, 2014a; Palacios, et al., 2012). Thus, 
the first challenge the clinician faces is the diagnosis of MDR-TB and evaluation of drug 
resistance pattern, leading to misdiagnosis or delayed diagnosis. Therefore, treatment of 
HIV-MDR-TB patients is initiated with empirical rather than DST-based individualized 
regimen, resulting in high rate of morbidity and mortality (Palacios et al., 2012; WHO, 
2014). Immunosuppression and overlapping toxicity of Highly Active Anti-retroviral 
Therapy (HAART) and anti-TB drugs causes a high incidence of adverse effects in HIV 
co-infected MDR-TB patients (WHO, 2014a; Hoffmann, et al., 2007). This makes the 
treatment of MDR-TB further challenging and can lead to high rate of TB treatment 
failure (WHO, 2014a; Palacios, et al., 2012; Wells, et al., 2007). Furthermore, the 
complex medication schedule is another possible reason for the poor treatment outcomes 
in this group of patients (Kang, et al., 2013). However, there are certain studies which 
have reported no impact of HIV co-infection on MDR-TB treatment outcomes (Ahuja, et 
al., 2012; Leimane, et al., 2005; Marais, et al., 2014).  
1.7.3 Resistance to fluoroquinolones  
Fluoroquinolones are broad spectrum antibiotics. These agents due their fast 
bactericidal and sterilizing effects make the backbone of MDR-TB treatment (Falzon, et 
al., 2013; Migliori, et al., 2012). The published literature has extensively reported the 
use of fluoroquinolones with susceptibility as a predictor of favorable treatment 
outcomes in MDR-TB patients (Ahuja, et al., 2012; Akcakir, 2011; Anderson, et al., 
2013; Bastos, et al., 2014; Chiang, et al., 2006; Kwak, et al., 2015). A recently 
published meta-analysis which analyzed the individual data from 31 cohorts has reported 
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the in-vitro susceptibility to fluoroquinolones as a significant and consistent predictor of 
successful treatment outcomes in both MDR as well as extensively drug resistant-TB 
(XDR-TB) patients (Bastos, et al., 2014). This association is supported by another meta-
analysis which included the individual data of 6724 M/XDR-TB patients from 26 
centers (Falzon, et al., 2013). On the other hand, various individual studies, meta-
analyses and systematic reviews have reported resistance to fluoroquinolones as an 
independent risk factor for unsuccessful treatment outcomes in MDR-TB patients 
(Johnston, et al., 2009; Kliiman & Altraja, 2009; Kurbatova, et al., 2012; Leimane, et 
al., 2005; Smith, et al., 2015).  
1.7.4 Resistance to injectable second-line anti-TB drugs 
Injectable SLD (amikacin, kanamycin and capreomycin) along with 
fluoroquinolones plays a central role in the management of MDR-TB (Bastos, et al., 
2014; Falzon, et al., 2013; WHO, 2014a). In a South Korean cohort, odd of favorable 
treatment outcomes in MDR-TB patients susceptible to kanamycin was greater than 
those who were susceptible to fluoroquinolones (Franke, et al., 2008). Sufficient data are 
available reporting unfavorable treatment outcomes among MDR-TB patients with 
additional resistance to an injectable SLD. A multi-country study which included MDR-
TB patients from Germany, Italy, Estonia and Russian Federation has reported resistance 
to capreomycin as a risk factor for poor treatment outcomes (Migliori, et al., 2008). A 
study recently conducted in Russia has also reported resistance to capreomycin as a risk 
factor for poor treatment outcomes in MDR-TB patients (Smith, et al., 2015). These 
findings have been complemented by a meta-analysis of individual data of 6724 MDR-
TB patients from 26 centers, which has reported a high risk of unsuccessful treatment 
outcomes in MDR-TB patients with additional resistance to an injectable SLD (Falzon, 
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et al., 2013). A recently conducted meta-analysis of individual data of 8955 MDR-TB 
patients corroborated the positive association between in-vitro susceptibility to an 
injectable SLD and higher odds of treatment success (Bastos, et al., 2014). 
1.7.5 Low body mass index 
Being a marker of the severity of a disease and poor nutritional and 
socioeconomic status, low BMI (<18.5 kg/m2) at the onset of treatment has widely been 
reported a risk factor of poor treatment outcomes in both MDR as well as XDR-TB 
patients. A systematic review of 31 cohorts of MDR-TB patients has reported low BMI 
as a risk factor for unsuccessful treatment outcomes (Johnston et al., 2009). Similar 
finding has been reported by various individual studies conducted elsewhere (Farley, et 
al., 2011; Holtz, et al., 2006; Kurbatova, et al., 2012; Leimane, et al., 2005; Malla, et 
al., 2009; C. Mitnick, et al., 2003; Tang, et al., 2013). On the other hand, higher odds of 
successful treatment outcomes have been reported in MDR and XDR-TB patients with 
baseline BMI > 18.5 Kg/m2 (Kwon, et al., 2008).  Studies in which patient’s heights was 
not measured to calculate BMI, patients’ lower body weight at base-line visit has been 
reported as a risk factor for unsuccessful treatment outcomes. An Ethiopian study has 
reported TB patient’s baseline body weight <40 kg as a risk factor of unsuccessful 
treatment outcomes (Biruk et al., 2016). In a study conducted at PMDT unit Multan, 
lower body weight (< 40 kg) of MDR- TB patients at baseline visit has been reported a 
predictor of death. Those with baseline weight < 40 kg were two times more likely to 
develop death (Javaid et al., 2016). Likewise, in a prospective cohort of MDR-TB 
patients with high prevalence of HIV, patient’s baseline body weight <45 kg was 
associated significantly with high hazards of death and treatment failure (Farley et al., 
2011). 
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1.7.6 Diabetes mellitus 
Diabetes mellitus, in addition to be a risk factor for the development of drug 
resistant TB (Gomes, et al., 2014; Rifat, et al., 2014) is also reported as a predictor of 
unsuccessful outcomes in drug susceptible (Alisjahbana, et al., 2007; Dooley, et al., 
2009; Wang, et al., 2009) as well as resistant TB patients (Kang, et al., 2013; Tang, et 
al., 2013). Poor sterilizing effects of anti-microbial agents because of high bacterial 
load, and impaired cell mediated immunity due to alterations in monocyte 
chemoattraction, type 1 cytokine phenotype and alveolar macrophage activity 
(Moutschen et al., 1991; Restrepo, et al., 2008; Yamashiro, et al., 2005) are the possible 
reasons for higher odds of unsuccessful treatment outcomes in diabetic TB patients. Sub-
therapeutic serum levels of anti-TB drugs due to malabsorption and altered 
pharmacokinetics (Kang et al., 2012), patients’ non-adherence with anti-TB therapy due 
to complex medication schedules and relatively high incidence of adverse events are the 
other possible contributing factors for poor treatment outcomes in this group of patients 
(Kang, et al., 2013; Tang, et al., 2013).  
1.7.7 Lung cavitation 
The presence of lung cavities is suggestive of severe and advanced disease. By 
reducing drug penetration, lung cavities decrease the efficacy of anti-TB drugs and 
hence increase the likelihood of unfavorable treatment outcomes (Yew, et al., 2000). A 
study from DOTS-Plus projects at five resource poor settings reported that cavitary 
disease at the baseline visit was an independent predictor of death among MDR-TB 
patients (Kurbatova, et al., 2012). Positive association between lung cavitation and poor 
treatment outcomes among MDR-TB patients is confirmed by various studies conducted 
